Tirzepatide
- Product Name
- Tirzepatide
- CAS No.
- 2023788-19-2
- Chemical Name
- Tirzepatide
- Synonyms
- GLP-1 RA;Tilpotide;Tilposide;GIP\GLP-1;Tirzepatide;Trizepatide;terzapitide;Tirzepatide(GLP-1);Trizepatide peptide;Tirzepatide (LY3298176)
- CBNumber
- CB24869395
- Formula Weight
- 0
- MOL File
- Mol file
Tirzepatide Property
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- Sequence
- Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Tirzepatide Chemical Properties,Usage,Production
Description
Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.
Uses
Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.
Definition
Mounjaro® and Ozempic® have distinct active ingredients: tirzepatide and semaglutide, respectively. However, both of these drugs are GLP-1 agonists, which bind to GLP-1 receptors, simulate a feeling of satiety, and signal the pancreas to produce insulin.
Trade name
brand name: Mounjaro
Mechanism of action
It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake, 4 and reduce body weight in patients with type 2 diabetes.
Pharmacology
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity and is currently under regulatory review as a treatment for adults with type 2 diabetes. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF). Studies of tirzepatide in obstructive sleep apnea (OSA) and in morbidity/mortality in obesity are planned as well.
Side effects
The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies that have been approved for the treatment of obesity. This said, reported side effects were considerable, especially as dosage levels increased. The most common adverse events were nausea (~30%), diarrhea (~20%), constipation (~15%) and vomiting (~10%).
If tirzepatide gets approved as a both a blood glucose control and anti-obesity agent, it could become a blockbuster drug. However, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles, which have plagued similar treatments.
Synthesis
The synthesis process of tirzepatide is as follows: to a reactor was charged dichloromethane (28.6 kg), water (5.4 kg), DTT (4.3 kg), Boc-Fragment 1 + 2 + 3 + 4 (14.3 kg, 8), and TIPS (3.3 kg), resulting in a slurry. The slurry was cooled to less than 10 °C before TFA (162 kg) was added over no more than 1.75 h, resulting in a solution. The solution was warmed to 21 °C and held at this temperature for 3 h. The solution was transferred to a separate reactor, rinsing with TFA (54.3 kg). This solution was cooled to ?10 °C and charged MTBE (125.8 kg) over 2 h. Then, additional MTBE (233 kg) was charged at 17 kg/h, maintaining an internal temperature of less than ?5 °C. The resulting slurry was warmed to 0 °C and then filtered. The wet cake was washed with MTBE (2 × 11 kg/kg relative to 8) and then dried under vacuum at no more than 35 °C to obtain tirzepatide (1, 8.71 kg, 1.81 mol, 81% yield)[1].
Mode of action
Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behaviour has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies have shown that this is due to tirzepatide mimicking the actions of natural GIP at the GIP receptor. However, at the GLP-1 receptor, tirzepatide shows bias towards cAMP (a messenger associated with regulation of glycogen, sugar and lipid metabolism) generation, rather than β-arrestin recruitment. This combination of preference towards GIP receptor and distinct signaling properties at GLP-1 suggest this biased agonism increases insulin secretion. Tirzepatide has also been shown to increase levels of adiponectin, an adipokine involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks, at the 10 mg dosage.
Clinical claims and research
Tirzepatide (Eli Lilly), a novel, once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 RA combination drug, has been developed to treat patients with T2DM. The manufacturer (Eli Lilly) announced the submission of a biologics license application with priority review to the FDA for T2DM on October 27, 2021, with a decision expected in mid-2022.
Research
Tirzepatide is in phase 3 clinical development at Eli Lilly and Company for blood glucose management in adults with type 2 diabetes, chronic weight management, and obesity-related heart failure with preserved ejection fraction. In addition, Tirzepatide is being studied as a potential treatment for non-alcoholic steatohepatitis (NASH). The molecule comprises a 39 amino acid peptide backbone and a side chain at residue 20. Of the 39 amino acids, 37 are naturally occurring (or coded), while two are noncoded aminoisobutyric acid residues at positions 2 and 13[1].
References
[1] Calley, J. and W. Dhillo. “Effects of the Hormone Kisspeptin on Reproductive Hormone Release in Humans.” 2014. 0.
Tirzepatide Preparation Products And Raw materials
Raw materials
Preparation Products
Tirzepatide Suppliers
- Tel
- 18014456767 18014456767
- wenxi@jszkhy.com
- Country
- China
- ProdList
- 1349
- Advantage
- 58
- Tel
- 028-87189093 18599944286
- 272503470@qq.com
- Country
- China
- ProdList
- 100
- Advantage
- 58
- Tel
- 0571-88211921 13355716090
- Sales@gotopbio.com
- Country
- China
- ProdList
- 2831
- Advantage
- 58
- Tel
- 0571-87213919
- Fax
- 0571-87213919
- eric@peptidego.com
- Country
- China
- ProdList
- 6347
- Advantage
- 58
- Tel
- 0571-86758863 13867485072
- Fax
- 0571-86758863
- lulu@thinheal.com
- Country
- China
- ProdList
- 300
- Advantage
- 58
- Tel
- 0571-88211921 15572296305
- sales4@gotopbio.com
- Country
- China
- ProdList
- 5144
- Advantage
- 58
- Tel
- 13989459766 18112526015
- sales@runyanpharma.com
- Country
- China
- ProdList
- 369
- Advantage
- 58
- Tel
- +86-028-64348587 15680781153
- sales@takelepeptide.com
- Country
- China
- ProdList
- 89
- Advantage
- 58
- Tel
- 18168071971
- support@yuan-peptide.com
- Country
- China
- ProdList
- 2977
- Advantage
- 58
- Tel
- 13327808530
- 2670965693@qq.com
- Country
- China
- ProdList
- 2179
- Advantage
- 58
View Lastest Price from Tirzepatide manufacturers
- Product
- Tirzepatide 2023788-19-2
- Price
- US $1.00/g
- Min. Order
- 1g
- Purity
- 99%
- Supply Ability
- 100kg
- Release date
- 2024-03-26
- Product
- Tirzepatide 2023788-19-2
- Price
- US $1.00/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 100kg
- Release date
- 2023-04-19
- Product
- Tirzepatide 2023788-19-2
- Price
- US $0.00/G
- Min. Order
- 1G
- Purity
- 99%
- Supply Ability
- 5kg
- Release date
- 2024-04-23